Erasca

Yahoo Finance • 10 days ago

ERASCA INVESTOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Erasca, Inc. on Behalf of Erasca Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Erasca (ERAS) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Erasca and would like to discus... Full story

Yahoo Finance • 10 days ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS

NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ: ERAS).  Such investors are advised to contact Danielle Peyton at newaction@pomla... Full story

Yahoo Finance • 12 days ago

Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally

On May 15, 2026, Cormorant Asset Management disclosed a new position in Dianthus Therapeutics(NASDAQ:DNTH), acquiring 950,000 shares in an estimated $55.01 million trade based on quarterly average pricing. What happened According to a Se... Full story

Yahoo Finance • 12 days ago

Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More

Key Points Cormorant Asset Management bought 5,800,000 Erasca shares in the first quarter, an estimated $68.55 million trade based on quarterly average pricing. The quarter-end position value rose by $93.84 million, reflecting both share... Full story

Yahoo Finance • 14 days ago

Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy

What happened According to an SEC filing dated May 15, 2026, Acuta Capital Partners, LLC initiated a new position in Erasca(NASDAQ:ERAS) during the first quarter. The fund acquired 354,575 shares, with an estimated transaction value of $4... Full story

Yahoo Finance • 15 days ago

ERAS SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS) investors concerning the Company’s and/or members o... Full story

Yahoo Finance • 18 days ago

How Investors Are Reacting To Erasca (ERAS) Wider Losses And Early Oncology Pipeline Efficacy Signs

Erasca, Inc. recently reported first-quarter 2026 results showing a net loss of US$183.44 million, alongside expanded clinical progress for its oncology pipeline. Despite the larger loss, the company highlighted robust early efficacy and g... Full story

Yahoo Finance • 18 days ago

Merck Broadens KEYTRUDA Collaborations As Patent Expiry Pressure Builds

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Merck (NYSE:MRK) is expanding clinical work around KEYTRUDA throug... Full story

Yahoo Finance • 18 days ago

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index down 0.3% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 19 days ago

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)

Erasca, Inc. ERAS-0015, a potentially best-in-class pan-RAS molecular glue, is being evaluated in combination with pembrolizumab SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology... Full story

Yahoo Finance • 19 days ago

ERAS Investors Have Opportunity to Join Erasca, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, May 10, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Erasca, Inc. (“Erasca” or “the Company”) (NASDAQ: ERAS)... Full story

Yahoo Finance • 19 days ago

JPMorgan Recommends Buying Erasca (ERAS) Stock at Current Levels

Erasca, Inc. (NASDAQ:ERAS) is one of the best performing healthcare stocks so far in 2026. The Fly reported on May 4 that JPMorgan is maintaining an Overweight rating on Erasca, Inc. (NASDAQ:ERAS) and recommends buying the stock at current... Full story

Yahoo Finance • 24 days ago

Erasca (ERAS) Announces Positive Preliminary Phase 1 Data for Pan-RAS Molecular Glue ERAS-0015

Erasca Inc. (NASDAQ:ERAS) is one of the best performing NASDAQ stocks according to Wall Street analysts. On April 27, Erasca announced positive preliminary Phase 1 data for ERAS-0015, a pan-RAS molecular glue targeting solid tumors. In pat... Full story

Yahoo Finance • 25 days ago

Erasca, Inc. Investors Should Contact Block & Leviton LLP to Learn More About Securities Fraud Investigation

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Erasca, Inc. (Nasdaq: ERAS) for potential securities law violations. Investors who have lost money in their Erasca, Inc. investment should contact the firm to lear... Full story

Yahoo Finance • 26 days ago

Buy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash Runways

Quick Read All three biotechs have dense 2026 clinical and regulatory milestone calendars that can drive outsized share movements, with cash runways stretching into 2028-2029 and strong analyst support despite pre-revenue status and binar... Full story

Yahoo Finance • 27 days ago

Revolution Medicines, Inc. (RVMD) One of the Best Stocks to Buy in a Rising Market amid $14B Opportunity

Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best stocks to buy in a rising market, according to Wall Street analysts. On April 27, shares of Erasca dropped sharply after Revolution Medicines Inc. (NASDAQ:RVMD) accused the company... Full story

Yahoo Finance • last month

Erasca Stock Sinks 48% in Race for Pancreatic Cancer Miracle Drug. What’s Behind the Sell-Off.

A confluence of safety concerns and underwhelming clinical data sent Erasca stock into a historic tailspin on Tuesday. Erasca late Monday reported positive Phase 1 trial results for ERAS-0015, a therapeutic drug candidate tailored to patie... Full story

Yahoo Finance • last month

Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L KRAS G12X PDAC: 40% uORR at 16-32 mg QD PA... Full story

Yahoo Finance • last month

Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015

SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven... Full story

Yahoo Finance • 3 months ago

Tango Therapeutics, Up 39% This Year, Surges Again On Another Cancer Pact

Shares of top 1% biotech stock Tango Therapeutics shot higher Thursday after the company agreed to codevelop a cancer treatment with Erasca. Continue Reading... Full story